Pomalidomide is used to treat a type of cancer in the bone marrow (multiple myeloma). It works by slowing or stopping the growth of cancer cells.
Pomalidomide was approved in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It has been approved for use in people who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Source Content : wikipedia
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Pomalidomide brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 / 9891296838 or Email Us to know more details about the medicine and its cost price in India.
The order for Pomalidomide will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
1. Velcade (bortezomib)
Generic Name: pomalidomide capsules, for oral use. Initial U.S. Approval: 2013
Capsules: 1 mg, 2 mg, 3 mg, and 4 mg
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Mektovi (Binimetinib) on prescription and Import License in Patient's Name only.
For overseas patients, Mektovi (Binimetinib) can be made available in Send your enquiry to find Mektovi (Binimetinib) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
European Commission Approves Empliciti (Elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone (EPd) For The Treatment Of Patients With Relapsed And Refractory Multiple Myeloma For More Details
Pomalidomide Receives FDA Breakthrough Designation for Kaposi Sarcoma. For More Details